Opaleye Management’s Standard BioTools LAB Stock Holding History

Opaleye Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-95,000	Closed	-$3.2M	–	40
2014 Q4	$3.2M	Buy	95,000 +28,000	+42%	+$793K	1.62%	23
2014 Q3	$1.64M	Buy	+67,000	New	+$1.88M	1.28%	24
2014 Q2	–	Sell	-90,000	Closed	-$3.97M	–	29
2014 Q1	$3.97M	Sell	90,000 -42,500	-32%	-$1.87M	2.93%	13
2013 Q4	$5.04M	Buy	+132,500	New	+$3.9M	3.95%	7

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management's LAB Position: Q1 2015 in Review

Opaleye Management sold out of Standard BioTools (LAB) in Q1 2015, closing a stake of 95,000 shares — an estimated $3.2M sold.

Opaleye Management first reported a position in LAB in Q4 2013 and held it in 4 quarters. The position peaked at $5.04M in Q4 2013. 104 funds tracked by Wall St. Rank hold LAB as of Q1 2015.

Opaleye Management reported no remaining Standard BioTools position as of Q1 2015 after selling out during the quarter.
Opaleye Management sold 95,000 Standard BioTools shares in Q1 2015, an estimated $3.2M.
Opaleye Management first reported a position in Standard BioTools in Q4 2013 and held it in 4 quarters.
Opaleye Management's Standard BioTools position peaked at $5.04M in Q4 2013.
104 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2015.

Based on Opaleye Management's 13F filing for Q1 2015, filed 15 May 2015.